La medicina regenerativa

Enguany, el premi Nobel de medicina i fisiologia és especialment significatiu per dos motius.

Transformació d'una màquina de tecnologia additiva per a la fabricació d'scaffolds

Grup de Recerca en Enginyeria de Producte, Procés i Producció de la Universitat de Girona té en les seves instal•lacions una RepRap model Prusa Mendel. Un dels seus àmbits d’investigació és el sector mèdic. Una de les aplicacions més innovadores de les tecnologies additives, emmarcada dins del camp mèdic, és la fabricació de scaffolds. En la medicina regenerativa, els scaffolds s’utilitzen com estructures biodegradables implantables que serveixen de base per a la correcte reproducció de teixit a partir de cèl•lules no diferenciades. L’objecte del projecte és aconseguir fabricar scaffolds amb la Reprap. Per tald’assolir aquest objectiu final caldran molts passos previs. En el moment que s’inicia elpresent projecte la RepRap té tots els seus components muntats, el cablejat instal•lat i el firmware inicial a la placa. Així, en primer lloc cal obtenir una correcta comunicació entre la màquina i l’ordinador a través del qual es podrà accedir a la placa per tal de realizar ajustaments. Una vegada la màquina obeeixi les ordres de moviment en la magnitud i la direcció desitjada serà el moment d’ajustar els paràmetres propis de la impressió. Aquests varien en funció de l’extrusor i el material a utilitzar. En aquest punt es passarà a dissenyar i fabricar diferents tipus de scaffolds variant les estratègies i les geometries. Aquests dissenys seran testats mecànicament a compressió. També seran analitzats geomètricament i se’n determinarà la porositat. Finalment, a partir de l’anàlisi dels resultats s’intentarà trobar una relació entre les diferents formes geomètriques, les porositats i la resistència

Disease-corrected haematopoietic progenitors from Fanconi anemia induced pluripotent stem cells

The generation of induced pluripotent stem (iPS) cells has enabled the derivation of patient-specific pluripotent cells andprovided valuable experimental platforms to model human disease. Patient-specific iPS cells are also thought to hold greattherapeutic potential, although direct evidence for this is still lacking. Here we show that, on correction of the genetic defect,somatic cells from Fanconi anaemia patients can be reprogrammed to pluripotency to generate patient-specific iPS cells. These cell lines appear indistinguishable from human embryonic stem cells and iPS cells from healthy individuals. Most importantly, we show that corrected Fanconi-anaemia-specific iPS cells can give rise to haematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically normal, that is, disease-free. These data offer proof-of-concept that iPS cell technology can be used for the generation of disease-corrected, patient-specific cells with potential value for cell therapy applications.

Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector

Induced pluripotent stem (iPS) cells have generated keen interestdue to their potential use in regenerative medicine. They havebeen obtained from various cell types of both mice and humans byexogenous delivery of different combinations of Oct4, Sox2, Klf4,c-Myc, Nanog, and Lin28. The delivery of these transcription factorshas mostly entailed the use of integrating viral vectors (retrovirusesor lentiviruses), carrying the risk of both insertional mutagenesisand oncogenesis due to misexpression of these exogenousfactors. Therefore, obtaining iPS cells that do not carry integratedtransgene sequences is an important prerequisite for their eventualtherapeutic use. Here we report the generation of iPS cell linesfrom mouse embryonic fibroblasts with no evidence of integrationof the reprogramming vector in their genome, achieved by nucleofectionof a polycistronic construct coexpressing Oct4, Sox2, Klf4,and c-Myc

Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions

The availability of induced pluripotent stem cells (iPSCs)has created extraordinary opportunities for modeling andperhaps treating human disease. However, all reprogrammingprotocols used to date involve the use of products of animal origin. Here, we set out to develop a protocol to generate and maintain human iPSC that would be entirelydevoid of xenobiotics. We first developed a xeno-free cellculture media that supported the long-term propagation of human embryonic stem cells (hESCs) to a similar extent as conventional media containing animal origin products or commercially available xeno-free medium. We also derivedprimary cultures of human dermal fibroblasts under strictxeno-free conditions (XF-HFF), and we show that they can be used as both the cell source for iPSC generation as well as autologous feeder cells to support their growth. We also replaced other reagents of animal origin trypsin, gelatin, matrigel) with their recombinant equivalents. Finally, we used vesicular stomatitis virus G-pseudotyped retroviral particles expressing a polycistronic construct encoding Oct4, Sox2, Klf4, and GFP to reprogram XF-HFF cells under xeno-free conditions. A total of 10 xeno-free humaniPSC lines were generated, which could be continuously passaged in xeno-free conditions and aintained characteristics indistinguishable from hESCs, including colonymorphology and growth behavior, expression of pluripotency-associated markers, and pluripotent differentiationability in vitro and in teratoma assays. Overall, the resultspresented here demonstrate that human iPSCs can be generatedand maintained under strict xeno-free conditions and provide a path to good manufacturing practice (GMP) applicability that should facilitate the clinical translation of iPSC-based therapies.

Derivation of human embryonic stem cells at the center for regenerative medicine in Barcelona

We report here the legislative issues related toembryo research and human embryonic stem cell (hESC)research in Spain and the derivation of nine hESC lines atthe Center of Regenerative Medicine in Barcelona. You canfind the information for obtaining our lines for researchpurposes at blc@cmrb.eu.

A protocol describing the genetic correction of somatic human cells and subsequent generation of IPS cell

The generation of patient-specific induced pluripotent stem cells (iPSCPSCPSCs) offers unprecedented opportunities for modeling and treating human disease. In combination with gene therapy, the iPSCPSCPSC technology can be used to generate disease-free progenitor cells of potential interest for autologous cell therapy. We explain a protocol for the reproducible generation of genetically corrected iPSCPSCPSCs starting from the skin biopsies of Fanconi anemia patients using retroviral transduction with OCT4, SOX2 and KLF4. Before reprogramming, the fibroblasts and/or keratinocytes of the patients are genetically corrected with lentiviruses expressing FANCA. The same approach may be used for other diseases susceptible to gene therapy correction. Genetically corrected, characterized lines of patient-specific iPSCPSCPSCs can be obtained in 4–5 months.

Generation of induced pluripotent stem cells from human cord blood cells with only two factors:OCT4 and SOX2

Induced pluripotent stem cells (iPSC ) provide an invaluable resource for regenerative medicine as they allow the generationof patient-specific progenitors with potential value for cell therapy. However, in many instances, an off-the-shelf approach isdesirable, such as for cell therapy of acute conditions or when the patient’s somatic cells are altered as a consequence of a chronicdisease or aging. Cord blood (CB) stem cells appear ideally suited for this purpose as they are young cells expected to carryminimal somatic mutations and possess the immunological immaturity of newborn cells; additionally, several hundred thousandimmunotyped CB units are readily available through a worldwide network of CB banks. Here we present a detailed protocol for thederivation of CB stem cells and how they can be reprogrammed to pluripotency by retroviral transduction with only two factors(OCT 4 and SO X2) in 2 weeks and without the need for additional chemical compounds.

Generation of cardiomyocytes from new human embrionic stem cell lines derived from poor-quanlity blastocysts

Human embryonic stem (hES) cells represent a potential source for cell replacement therapy of many degenerative diseases. Most frequently, hES cell lines are derived from surplus embryos from assisted reproduction cycles, independent of their quality or morphology. Here, we show that hES cell lines can be obtained from poor-quality blastocysts with the same efficiency as that obtained from good- or intermediate-quality blastocysts. Furthermore, we show that the self-renewal, pluripotency, and differentiation ability of hES cell lines derived from either source are comparable. Finally, we present a simple and reproducible embryoid body-based protocol for the differentiation of hES cells into functional cardiomyocytes. The five new hES cell lines derived here should widen the spectrum of available resources for investigating the biology of hES cells and advancing toward efficient strategies of regenerative medicine.

Les cèl·lules mare arriben a Barcelona

Una de les tecnologies biomèdiques naixents més esperançadores i controvertides és sens dubte la clonació terapèutica, que utilitza cèl·lules mare d'embrions humans. Fa un mes es va signar el contracte de creació del Centre d'Investigació en Medicina Regenerativa de Barcelona, que inclourà un dels bancs de cèl·lules mare més importants del món [...].

Immortalitat

Els humans sempre hem buscat la immortalitat, i potser de tant buscar-la en- cara no ens hem adonat que ja en som. Bé, de fet, com a persones individuals, no som pas immortals, però els nostres gens si que ho són. El raonament és molt simple: si tots els éssers vius descendim d'un mateix ancessor, tots haurem heretat característiques d'ell, codificades al material genètic. Per tant, en tots nosaltres sobreviuen característiques d'aquell reeixit intent vital primigeni, de la mateixa manera que en els nostres descendents, siguin humans o pertanyin a qualsevol altra espècie humanoide successora nostra que la selecció natural afavoreixi, si es dóna el cas, sobreviuran els nostres gens, assegurant-nos la immortalitat genètica [...].